Biofrontera’s (BFRI) “Buy” Rating Reaffirmed at Benchmark

Benchmark restated their buy rating on shares of Biofrontera (NASDAQ:BFRI) in a research report sent to investors on Friday,Benzinga reports. They currently have a $7.00 price target on the stock.

Biofrontera Price Performance

BFRI traded up $0.03 during midday trading on Friday, reaching $0.73. 259,073 shares of the company’s stock were exchanged, compared to its average volume of 1,008,151. The stock has a market capitalization of $4.07 million, a PE ratio of -0.32 and a beta of 0.50. The business’s 50-day moving average price is $1.02 and its 200 day moving average price is $1.09. Biofrontera has a 1-year low of $0.61 and a 1-year high of $4.04.

Biofrontera (NASDAQ:BFRI) last announced its earnings results on Wednesday, August 14th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.07. The company had revenue of $7.84 million during the quarter, compared to analysts’ expectations of $9.02 million. Biofrontera had a negative net margin of 36.31% and a negative return on equity of 652.37%. As a group, analysts expect that Biofrontera will post -3.11 EPS for the current fiscal year.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.